Investors | MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
Press Releases | MacroGenics, Inc.
Nov 6, 2025 · The Investor Relations website contains information about MacroGenics, Inc.'s business for stockholders, potential investors, and financial analysts.
1904 Presenter Contact Information: [email protected], [email protected]
Board of Directors - MacroGenics, Inc.
Prior to joining MacroGenics, Dr. Koenig served as Senior Vice President of Research at MedImmune, Inc., where he participated in the selection and maturation of its product pipeline.
Soluble ADAM Proteins ADAM17 (TACE) Presented at the American Association for Cancer Research 2024 Annual Meeting, April 5–10, 2024, San Diego, CA MacroGenics, Inc., San …
ACKNOWLEDGMENTS Funding for the CP-MGD019-01 study, this analysis, and medical writing support were provided by MacroGenics, Inc, Rockville, MD, USA.
E. Shenderov is founder and CEO of LifeImmune, Inc; has received clinical trial institutional research funding from MacroGenics, and has served as a consultant for Firstthought.io and …
efficacy tumor xenograft studies In vivo – Ef cacy studies and procedures were approved by MacroGenics, fi Inc. or ImmunoGen, Inc. Institutional Animal Care and Use Com-mittees in …
Dosing MGC018 displays antitumor activity toward heterogeneous B7-H3 expressing PDX models representing a range of solid cancers Presented at the American Association for Cancer …
Incyte and MacroGenics Announce Global Collaboration and …
Oct 25, 2017 · The combination of MacroGenics' technology platforms and protein engineering expertise has allowed MacroGenics to generate promising product candidates and enter into …